urea has been researched along with Hand-Foot Syndrome in 10 studies
pseudourea: clinical use; structure
isourea : A carboximidic acid that is the imidic acid tautomer of urea, H2NC(=NH)OH, and its hydrocarbyl derivatives.
Hand-Foot Syndrome: Chemotherapy-induced dermal side effects that are associated with the use of various CYTOSTATIC AGENTS. Symptoms range from mild ERYTHEMA and/or PARESTHESIA to severe ulcerative dermatitis with debilitating pain involving typically palmoplantar and intertriginous areas. These cutaneous manifestations are sometimes accompanied by nail anomalies.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study is validated the prophylactic efficacy of urea-based creams on sorafenib-induced hand-foot skin reaction in patients with advanced hepatocellular carcinoma." | 9.51 | Validation of the prophylactic efficacy of urea-based creams on sorafenib-induced hand-foot skin reaction in patients with advanced hepatocellular carcinoma: A randomised experiment study. ( Hu, SH; Lien, RY; Lu, LC; Lu, SF; Tung, HH; Wu, SL, 2022) |
| "Hand-foot skin reaction (HFSR) is the most common adverse event during sorafenib treatment in patients with hepatocellular carcinoma (HCC)." | 9.34 | Effect of urea cream on sorafenib-associated hand-foot skin reaction in patients with hepatocellular carcinoma: A multicenter, randomised, double-blind controlled study. ( Cho, SB; Hong, YM; Hwang, SY; Jang, BK; Jang, ES; Jang, JY; Jung, YK; Kim, DY; Kim, HJ; Kim, JH; Kim, MY; Lee, HW; Lee, JH; Lee, YS; Seo, YS; Yim, HJ; Yoon, KT, 2020) |
| "To assess whether urea-based cream (UBC) has prophylactic benefits on sorafenib-induced hand-foot skin reaction (HFSR) in patients with advanced hepatocellular carcinoma (HCC)." | 9.20 | Randomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-associated hand-foot skin reactions in patients with advanced hepatocellular carcinoma. ( Bai, Y; Guo, X; Kang, H; Lu, L; Lu, M; Qu, Z; Ren, Z; Shi, L; Song, T; Wang, H; Wang, X; Yang, W; Yang, Y; Ye, SL; Zhou, W; Zhu, K, 2015) |
| "Patients with GI tumors or breast cancer treated with capecitabine were included in this randomized phase III study." | 9.20 | Mapisal Versus Urea Cream as Prophylaxis for Capecitabine-Associated Hand-Foot Syndrome: A Randomized Phase III Trial of the AIO Quality of Life Working Group. ( Al-Batran, SE; Bolz, G; Gencer, D; Hegewisch-Becker, S; Hofheinz, RD; Kronawitter, U; Loeffler, LM; Potenberg, J; Schneeweiss, A; Schulz, H; Stahl, M; Tauchert, F, 2015) |
| "The aim of this study is validated the prophylactic efficacy of urea-based creams on sorafenib-induced hand-foot skin reaction in patients with advanced hepatocellular carcinoma." | 5.51 | Validation of the prophylactic efficacy of urea-based creams on sorafenib-induced hand-foot skin reaction in patients with advanced hepatocellular carcinoma: A randomised experiment study. ( Hu, SH; Lien, RY; Lu, LC; Lu, SF; Tung, HH; Wu, SL, 2022) |
| "Hand-foot skin reaction (HFSR) is the most common adverse event during sorafenib treatment in patients with hepatocellular carcinoma (HCC)." | 5.34 | Effect of urea cream on sorafenib-associated hand-foot skin reaction in patients with hepatocellular carcinoma: A multicenter, randomised, double-blind controlled study. ( Cho, SB; Hong, YM; Hwang, SY; Jang, BK; Jang, ES; Jang, JY; Jung, YK; Kim, DY; Kim, HJ; Kim, JH; Kim, MY; Lee, HW; Lee, JH; Lee, YS; Seo, YS; Yim, HJ; Yoon, KT, 2020) |
| "To assess whether urea-based cream (UBC) has prophylactic benefits on sorafenib-induced hand-foot skin reaction (HFSR) in patients with advanced hepatocellular carcinoma (HCC)." | 5.20 | Randomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-associated hand-foot skin reactions in patients with advanced hepatocellular carcinoma. ( Bai, Y; Guo, X; Kang, H; Lu, L; Lu, M; Qu, Z; Ren, Z; Shi, L; Song, T; Wang, H; Wang, X; Yang, W; Yang, Y; Ye, SL; Zhou, W; Zhu, K, 2015) |
| "Patients with GI tumors or breast cancer treated with capecitabine were included in this randomized phase III study." | 5.20 | Mapisal Versus Urea Cream as Prophylaxis for Capecitabine-Associated Hand-Foot Syndrome: A Randomized Phase III Trial of the AIO Quality of Life Working Group. ( Al-Batran, SE; Bolz, G; Gencer, D; Hegewisch-Becker, S; Hofheinz, RD; Kronawitter, U; Loeffler, LM; Potenberg, J; Schneeweiss, A; Schulz, H; Stahl, M; Tauchert, F, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (60.00) | 24.3611 |
| 2020's | 4 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lien, RY | 1 |
| Tung, HH | 1 |
| Wu, SL | 1 |
| Hu, SH | 1 |
| Lu, LC | 1 |
| Lu, SF | 1 |
| Shou, L | 1 |
| Chen, J | 1 |
| Shao, T | 1 |
| Zhang, Y | 1 |
| Zhao, S | 1 |
| Chen, S | 1 |
| Shu, Q | 1 |
| Gialaim Purcino Dos Reis, FC | 1 |
| Menêses, AG | 1 |
| Mazoni, SR | 1 |
| Pereira Silveira, RCC | 1 |
| Diniz Dos Reis, PE | 1 |
| Vasques, CI | 1 |
| Lee, YS | 1 |
| Jung, YK | 1 |
| Kim, JH | 1 |
| Cho, SB | 1 |
| Kim, DY | 1 |
| Kim, MY | 1 |
| Kim, HJ | 1 |
| Seo, YS | 1 |
| Yoon, KT | 1 |
| Hong, YM | 1 |
| Lee, JH | 1 |
| Lee, HW | 1 |
| Yim, HJ | 1 |
| Jang, BK | 1 |
| Jang, ES | 1 |
| Jang, JY | 1 |
| Hwang, SY | 1 |
| Ren, Z | 1 |
| Zhu, K | 1 |
| Kang, H | 1 |
| Lu, M | 1 |
| Qu, Z | 1 |
| Lu, L | 1 |
| Song, T | 1 |
| Zhou, W | 1 |
| Wang, H | 1 |
| Yang, W | 1 |
| Wang, X | 1 |
| Yang, Y | 1 |
| Shi, L | 1 |
| Bai, Y | 1 |
| Guo, X | 1 |
| Ye, SL | 2 |
| Hofheinz, RD | 2 |
| Gencer, D | 1 |
| Schulz, H | 1 |
| Stahl, M | 1 |
| Hegewisch-Becker, S | 1 |
| Loeffler, LM | 1 |
| Kronawitter, U | 1 |
| Bolz, G | 1 |
| Potenberg, J | 1 |
| Tauchert, F | 1 |
| Al-Batran, SE | 1 |
| Schneeweiss, A | 2 |
| Negri, FV | 1 |
| Porta, C | 1 |
| Burkholder, I | 1 |
| Iwase, S | 1 |
| Ishiki, H | 1 |
| Watanabe, A | 1 |
| Shimada, N | 1 |
| Chiba, T | 1 |
| Kinkawa, J | 1 |
| Tojo, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Re-validating Prophylactic Efficacy of Urea-based Cream on Sorafenib-induced Hand-foot Skin Reaction in Patients With Advanced Hepatocellular Carcinoma[NCT04568330] | 129 participants (Actual) | Interventional | 2014-03-21 | Completed | |||
| The Effect of Urea Cream on Sorafenib-associated Hand-Foot Skin Reaction in Patients With Korean Hepatocellular Carcinoma Patients: Multicenter, Prospective Randomized Double-Blind Controlled Study[NCT03212625] | Phase 4 | 288 participants (Actual) | Interventional | 2016-01-28 | Completed | ||
| A Phase II, Randomised Controlled Trial to Evaluate the Efficacy and Safety of Moisturising Creams With or Without Palm-oil-derived Vitamin E Concentrate in Addition to Urea-based Cream or Urea-based Cream Alone in Capecitabine-associated Palmar-Plantar E[NCT05939726] | 90 participants (Anticipated) | Interventional | 2023-05-16 | Recruiting | |||
| A Randomized, Open-label Phase III Trial of Mapisal® Versus an Urea Hand-foot Cream as Prophylaxis for Capecitabine-induced Hand-foot Syndrome in Patients With Gastrointestinal Tumors or Breast Cancer[NCT01626781] | 0 participants | Expanded Access | No longer available | ||||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for urea and Hand-Foot Syndrome
| Article | Year |
|---|---|
Topical interventions for preventing hand-foot syndrome resulting from antineoplastic therapy: A scoping review.
Topics: Academies and Institutes; Antineoplastic Agents; Databases, Factual; Hand-Foot Syndrome; Humans; Ure | 2023 |
4 trials available for urea and Hand-Foot Syndrome
| Article | Year |
|---|---|
Validation of the prophylactic efficacy of urea-based creams on sorafenib-induced hand-foot skin reaction in patients with advanced hepatocellular carcinoma: A randomised experiment study.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Hand-Foot Syndrome; Humans; Liver Neoplasms; Niaci | 2022 |
Effect of urea cream on sorafenib-associated hand-foot skin reaction in patients with hepatocellular carcinoma: A multicenter, randomised, double-blind controlled study.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Double-Blind Method; Female; Hand-Foot Syndr | 2020 |
Randomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-associated hand-foot skin reactions in patients with advanced hepatocellular carcinoma.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocel | 2015 |
Randomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-associated hand-foot skin reactions in patients with advanced hepatocellular carcinoma.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocel | 2015 |
Randomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-associated hand-foot skin reactions in patients with advanced hepatocellular carcinoma.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocel | 2015 |
Randomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-associated hand-foot skin reactions in patients with advanced hepatocellular carcinoma.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocel | 2015 |
Mapisal Versus Urea Cream as Prophylaxis for Capecitabine-Associated Hand-Foot Syndrome: A Randomized Phase III Trial of the AIO Quality of Life Working Group.
Topics: Administration, Cutaneous; Adult; Aged; Antimetabolites, Antineoplastic; Antioxidants; Breast Neopla | 2015 |
Mapisal Versus Urea Cream as Prophylaxis for Capecitabine-Associated Hand-Foot Syndrome: A Randomized Phase III Trial of the AIO Quality of Life Working Group.
Topics: Administration, Cutaneous; Adult; Aged; Antimetabolites, Antineoplastic; Antioxidants; Breast Neopla | 2015 |
Mapisal Versus Urea Cream as Prophylaxis for Capecitabine-Associated Hand-Foot Syndrome: A Randomized Phase III Trial of the AIO Quality of Life Working Group.
Topics: Administration, Cutaneous; Adult; Aged; Antimetabolites, Antineoplastic; Antioxidants; Breast Neopla | 2015 |
Mapisal Versus Urea Cream as Prophylaxis for Capecitabine-Associated Hand-Foot Syndrome: A Randomized Phase III Trial of the AIO Quality of Life Working Group.
Topics: Administration, Cutaneous; Adult; Aged; Antimetabolites, Antineoplastic; Antioxidants; Breast Neopla | 2015 |
5 other studies available for urea and Hand-Foot Syndrome
| Article | Year |
|---|---|
Clinical characteristics, treatment outcomes, and prognosis in patients with MKIs-associated hand-foot skin reaction: a retrospective study.
Topics: Hand-Foot Syndrome; Humans; Ointments; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; R | 2023 |
Reply to F.V. Negri et al.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Emulsions; Female; Hand-Foot Syndrome; Humans; Liv | 2015 |
Urea-Based Cream to Prevent Sorafenib-Induced Hand-and-Foot Skin Reaction: Which Evidence?
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Emulsions; Female; Hand-Foot Syndrome; Humans; Liv | 2015 |
Reply to S. Iwase et al.
Topics: Antimetabolites, Antineoplastic; Antioxidants; Deoxycytidine; Female; Fluorouracil; Hand-Foot Syndro | 2016 |
Mapisal Versus Urea Cream as Prophylaxis for Capecitabine-Associated Hand-Foot Syndrome.
Topics: Antimetabolites, Antineoplastic; Antioxidants; Deoxycytidine; Female; Fluorouracil; Hand-Foot Syndro | 2016 |